超声弹性成像技术定量检测肝脏脂肪变的研究进展
Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization.
机构信息
From the Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Tex (D.T.F.); Departments of Medical Physics (I.M.R.M., T.J.H.) and Radiology (I.M.R.M.), University of Wisconsin, Institutes for Medical Research, 1111 Highland Ave, Room 1005, Madison, WI 53705; General Electric Healthcare, Milwaukee, Wis (M.W.); Department of Radiology, University of Alabama at Birmingham, Birmingham, Ala (M.L.R.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.O.); U.S. Food and Drug Administration, Silver Spring, Md (K.A.W.); Department of Electrical and Computer Engineering, University of Rochester, Rochester, NY (J.O.); Department of Natural Sciences, Kettering University, Flint, Mich (T.A.S.); Departments of Biomedical Engineering and Radiology, University of Michigan, Ann Arbor, Mich (J.B.F.); RSNA Quantitative Imaging Biomarkers Alliance (T.J.H.); and Center for Ultrasound Research & Translation, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.E.S.).
出版信息
Radiology. 2022 Nov;305(2):265-276. doi: 10.1148/radiol.212808. Epub 2022 Sep 13.
Excessive liver fat (steatosis) is now the most common cause of chronic liver disease worldwide and is an independent risk factor for cirrhosis and associated complications. Accurate and clinically useful diagnosis, risk stratification, prognostication, and therapy monitoring require accurate and reliable biomarker measurement at acceptable cost. This article describes a joint effort by the American Institute of Ultrasound in Medicine (AIUM) and the RSNA Quantitative Imaging Biomarkers Alliance (QIBA) to develop standards for clinical and technical validation of quantitative biomarkers for liver steatosis. The AIUM Liver Fat Quantification Task Force provides clinical guidance, while the RSNA QIBA Pulse-Echo Quantitative Ultrasound Biomarker Committee develops methods to measure biomarkers and reduce biomarker variability. In this article, the authors present the clinical need for quantitative imaging biomarkers of liver steatosis, review the current state of various imaging modalities, and describe the technical state of the art for three key liver steatosis pulse-echo quantitative US biomarkers: attenuation coefficient, backscatter coefficient, and speed of sound. Lastly, a perspective on current challenges and recommendations for clinical translation for each biomarker is offered.
过量的肝脏脂肪（脂肪变性）现在是全世界最常见的慢性肝病病因，也是肝硬化和相关并发症的独立危险因素。准确且具有临床应用价值的诊断、风险分层、预后评估和治疗监测需要以可接受的成本进行准确可靠的生物标志物测量。本文描述了美国超声医学研究所（AIUM）和 RSNA 定量成像生物标志物联盟（QIBA）为开发肝脂肪变性定量生物标志物的临床和技术验证标准所做的共同努力。AIUM 肝脏脂肪定量工作组提供临床指导，而 RSNA QIBA 脉冲回波定量超声生物标志物委员会则开发了测量生物标志物和降低生物标志物变异性的方法。在本文中，作者提出了对肝脏脂肪定量成像生物标志物的临床需求，回顾了各种成像方式的现状，并描述了三种关键的肝脏脂肪变性脉冲回波定量超声生物标志物的技术现状：衰减系数、背向散射系数和声速。最后，对每种生物标志物的当前挑战和临床转化建议进行了展望。
Zotero 插件